ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Psychomotor Agitation
Brain Diseases
Neurodegenerative Diseases

Alzheimer's Disease trials near Montréal, QC, CAN:

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Montreal, Quebec, Canada and 117 other locations

Status recently updated

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

Phase 2

Acumen Pharmaceuticals

Greenfield Park, Quebec, Canada and 96 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Montreal, Quebec, Canada and 168 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: Lecanemab

Phase 3

Eisai
Eisai

Greenfield Park, Quebec, Canada and 246 other locations

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...

Enrolling
Alzheimer's Disease
Drug: GSK4527226
Other: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Greenfield Park, Quebec, Canada and 103 other locations

Locations recently updated

study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Montreal, Quebec, Canada and 203 other locations

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: JNJ-63733657
Drug: Placebo

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Montreal, Quebec, Canada and 122 other locations

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Active, not recruiting
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

Phase 2

Biogen
Biogen

Montréal, Quebec, Canada and 137 other locations

female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis rela...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: Placebo
Drug: KarXT

Phase 3

Karuna Therapeutics
Karuna Therapeutics

Montreal, Quebec, Canada and 152 other locations

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

Phase 3

Lilly
Lilly

Montréal, Quebec, Canada and 312 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems